Novo Nordisk Sues Eli Lilly Over Obesity Drug Marketing

The legal challenge targets advertisements for Eli Lilly’s Zepbound and Mounjaro. Novo Nordisk contends that these promotions violate federal false advertising and unfair competition statutes by unfairly juxtaposing the highest doses of Lilly’s products against lower-dose versions of Novo’s competing drugs. By skewing these comparisons, Novo argues, the marketing strategy creates a distorted perception of efficacy for potential patients.

This litigation intensifies the rivalry between the two pharmaceutical titans as they scramble to dominate a sector projected to exceed $100 billion in the United States by 2030. While Novo Nordisk insists that court intervention is necessary to protect consumers from misinformation, industry analysts remain unconvinced that legal action will successfully resolve the underlying marketing dispute.